Literature DB >> 11701277

Long-term outcome of patients with West syndrome.

R Riikonen1.   

Abstract

The long-term outcome of Finnish children with West syndrome was evaluated. Two hundred and fourteen patients were followed up for 20-35 years or until death. A third of the patients died before the age of 3 years. The most common cause of death was infection. Autopsy revealed brain anomalies in 25 of 38 (66%) autopsied patients. Intellectual outcome was normal or slightly impaired in a quarter of the patients. All of them completed their education at a normal school or in a school for the educationally impaired children. Another fourth were taught in special training schools. Specific cognitive deficits were seen in some patients with normal intelligence. Nine attended secondary schools and seven of them had a professional occupation. Ten were married and five had children. One third of the patients were seizure-free, another third had seizures daily or monthly, and the remaining patients had seizures less frequently. Factors associated with a good prognosis were cryptogenic etiology, normal development before the onset of the spasms, a short treatment lag, and a good response to adrenocorticotropic hormone; this was seen in both the symptomatic and the cryptogenic group, and there were no relapses. In this study, the late appearance of focal abnormalities in electroencephalography was not associated with an unfavorable outcome. Focal abnormalities in temporal region were often seen in patients with autism. The location of an abnormality may be of importance for the prognosis. In this study, all the patients (100%) could be followed, which may be due to the special circumstances characteristic of Finland. The outcome in children with West syndrome seems to be better than is generally believed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701277     DOI: 10.1016/s0387-7604(01)00307-2

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  28 in total

Review 1.  Neuropsychological deficits in childhood epilepsy syndromes.

Authors:  William S MacAllister; Sarah G Schaffer
Journal:  Neuropsychol Rev       Date:  2007-10-26       Impact factor: 7.444

2.  A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

Authors:  Emmanuel Raffo; Antonietta Coppola; Tomonori Ono; Stephen W Briggs; Aristea S Galanopoulou
Journal:  Neurobiol Dis       Date:  2011-04-12       Impact factor: 5.996

Review 3.  Infantile spasms: review of the literature and personal experience.

Authors:  Alberto Fois
Journal:  Ital J Pediatr       Date:  2010-02-08       Impact factor: 2.638

4.  Effectiveness and Safety of Different Once-Daily Doses of Adrenocorticotropic Hormone for Infantile Spasms.

Authors:  Jinghua Yin; Qianjin Lu; Fei Yin; Ying Wang; Fang He; Liwen Wu; Lifen Yang; Xiaolu Deng; Chen Chen; Jing Peng
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

Review 5.  Inflammation in Epileptic Encephalopathies.

Authors:  Oleksii Shandra; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Adv Protein Chem Struct Biol       Date:  2017-02-28       Impact factor: 3.507

6.  Epilepsy: Update to guidelines on treatment of infantile spasms.

Authors:  Raili Riikonen
Journal:  Nat Rev Neurol       Date:  2012-08-07       Impact factor: 42.937

Review 7.  Recent advances in the pharmacotherapy of infantile spasms.

Authors:  Raili Riikonen
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 8.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

9.  PET in infancy predicts long-term outcome during adolescence in cryptogenic West syndrome.

Authors:  J Natsume; N Maeda; K Itomi; H Kidokoro; N Ishihara; H Takada; A Okumura; T Kubota; K Miura; K Aso; T Morikawa; K Kato; T Negoro; K Watanabe
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-27       Impact factor: 3.825

10.  Infantile spasms is associated with deletion of the MAGI2 gene on chromosome 7q11.23-q21.11.

Authors:  Christian R Marshall; Edwin J Young; Ariel M Pani; Mary-Louise Freckmann; Yves Lacassie; Cédric Howald; Kristi K Fitzgerald; Maarit Peippo; Colleen A Morris; Kate Shane; Manuela Priolo; Masafumi Morimoto; Ikuko Kondo; Esra Manguoglu; Sibel Berker-Karauzum; Patrick Edery; Holly H Hobart; Carolyn B Mervis; Orsetta Zuffardi; Alexandre Reymond; Paige Kaplan; May Tassabehji; Ronald G Gregg; Stephen W Scherer; Lucy R Osborne
Journal:  Am J Hum Genet       Date:  2008-06-19       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.